前列地尔联合缬沙坦治疗早期糖尿病肾病的临床分析

Clinical analysis of alprostadil combined with valsartan in the treatment of early diabetic nephropathy

目的:探讨前列地尔联合缬沙坦治疗早期糖尿病肾病的临床疗效性与肾脏保护性。方法:收治早期糖尿病肾病患者104例,随机均分两组,均给予饮食、运动、降糖等常规治疗。对照组单纯用药缬沙坦,试验组在对照组治疗基础上加用前列地尔。对比观察相关指标。结果:观察组患者血肌酐(Scr)和24 h UAE优于对照组,两组比较差异有统计学意义(P<0.05)。结论:前列地尔联合缬沙坦治疗糖尿病肾病可显著降低糖尿病肾病患者蛋白尿,有效改善患者肾功能,短期疗效良好,对延缓糖尿病肾病进展具有积极意义,且用药安全可靠。

Objective:To investigate the clinical efficacy and renal protection of alprostadil combined with valsartan in the treatment of early diabetic nephropathy.Methods:A total of 104 patients with early diabetic nephropathy were selected,they were randomly divided into the two groups equally,they were all given conventional treatment such as diet,exercise and hypoglycemic control.In the control group,patients were treated with valsartan alone,while patients in the experimental group were treated with alprostadil on the basis of treatment in the control group.The relevant indicators were compared and observed.Results:The serum creatinine(Scr)and 24 hUAE in the observation group were better than those in the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion:Alprostadil combined with valsartan can significantly reduce proteinuria in patients with diabetic nephropathy,improve renal function,improve short-term efficacy,and have positive effects on delaying the progression of diabetic nephropathy.The use of alprostadil in combination with valsartan is safe and reliable.